#Cannabis Stock News: Organigram (TSX VENTURE:OGI) (OTCQB: $OGRMF) Reports Q3 Financial Results - Increased Product Quality - 25% Patient Growth
MONCTON, NEW BRUNSWICK - July 28, 2017 (Investorideas.com Newswire) Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) ("Organigram" or the "Company") announces the financial results for the quarter ending May 31, 2017.
Organigram's financial results for the quarter completed May 31, 2017 included expenses associated with the implementation of an industry leading quality assurance program (the "QA Program"). The QA Program was implemented to ensure that the Company produces the highest quality product available in the marketplace and in response to a previously announced voluntary recall of certain product produced in 2016.
As a result of Organigram's increased focus on product quality and safety with the stated objective of establishing a leadership position in such regard within the industry, the Company focused on introducing product of the highest quality to the market. In practice, the program effectively identified product lots that were to be removed from inventory well before being introduced to the marketplace. The successful implementation of this program resulted in a reduction in inventory value for the quarter.
Organigram is pleased with the results and progress made during the quarter from an operational perspective and management is confident that these actions build the foundation for long-term success for the Company. This focus on product quality contributed to a 25% net increase in registered patients in Q3 when compared to Q2.
Additionally, the Company continued to make significant headway in increasing its overall production capacity and ensuring that it is prepared to be a market leader in the proposed adult-use recreational market in anticipation of a late-June 2018 adult recreational program launch date.
Selected highlights from the quarter include the following:
"Our number one priority in Q3 was ensuring that product quality and safety remain a stated objective of Organigram," stated Greg Engel, Chief Executive Officer of Organigram. "Through the implementation of a tier-one quality assurance program and improved production techniques, the Company will ensure that only the finest quality product is sold to clients of Organigram. We are confident that these actions result in Organigram being well poised for future success." Engel continued, "our facility is among the best across Canada and with our geographical-based cost advantages and improved product quality, I am very optimistic about the ability of the Company to maximize stakeholder value going forward."
Due to the implementation of the enhanced QA Program which resulted in less product being introduced to the market than originally contemplated, Organigram recognized indirect production expenses of $1.1 million related to inventory destruction, and a loss of $1.6 million due to fair value adjustment to biological assets and net realizable reduction to inventory. As a result, the Company generated adjusted EBITDA of ($1.5) million and cash flow of ($1.1) million. Organigram's cash and short-term investment balance was in excess of $48 million as at May 31, 2017.
Again in Q3, Organigram made significant progress with its onsite expansion initiatives as the Company has continued with progress towards increasing production capacity by an additional 10,000 kg's annually by the end of December, 2017. Due to the anticipated delay in the timing for the allowance of edible products, the construction and implementation of the planned commercial scale oils and extracts manufacturing facility has been deferred and the recently announced high-volume supercritical CO2 equipment from Advanced Extraction Systems ("AES") will be placed in our existing facility.
For more information, visit www.organigram.ca
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
Organigram Holdings Inc.
Chief Executive Officer
Organigram Holdings Inc.
Director of Investor and Media Relations
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing
Watch the 420 Cannabis Investor video
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.